As the U.S. market navigates a turbulent landscape marked by volatile trading sessions and fluctuating economic indicators, investors are closely watching the impact of ongoing tariff developments and bank earnings on major indices like the Dow Jones Industrial Average, which recently experienced significant swings. In such an environment, identifying high-growth tech stocks requires careful consideration of their resilience to macroeconomic pressures and potential for innovation amidst shifting trade policies.
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 20.44% | 29.79% | ★★★★★★ |
TG Therapeutics | 26.03% | 37.60% | ★★★★★★ |
Alkami Technology | 20.46% | 85.16% | ★★★★★★ |
Travere Therapeutics | 28.56% | 65.75% | ★★★★★★ |
Arcutis Biotherapeutics | 25.76% | 58.17% | ★★★★★★ |
Alnylam Pharmaceuticals | 22.73% | 58.77% | ★★★★★★ |
TKO Group Holdings | 22.48% | 25.17% | ★★★★★★ |
AVITA Medical | 28.21% | 56.12% | ★★★★★★ |
Lumentum Holdings | 21.61% | 120.49% | ★★★★★★ |
Ascendis Pharma | 32.36% | 59.79% | ★★★★★★ |
Click here to see the full list of 231 stocks from our US High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Arcturus Therapeutics Holdings Inc. focuses on developing vaccines for infectious diseases and products targeting liver and respiratory rare diseases, with a market cap of $266.32 million.
Operations: The company generates revenue primarily from the research and development of medical applications, totaling $152.31 million.
Arcturus Therapeutics Holdings, despite a challenging fiscal year with a net loss widening to $80.94 million from $29.73 million, shows promise in its innovative vaccine development segment. The FDA's Fast Track Designation for ARCT-2304, a self-amplifying mRNA vaccine against influenza A H5N1, underscores its potential in addressing global health risks with cutting-edge technology. This recognition could expedite the development process and enhance communication with regulatory bodies, potentially positioning Arcturus at the forefront of pandemic response innovations. Meanwhile, revenue forecasts anticipate robust growth at 37% annually, outpacing the industry average significantly.
Gain insights into Arcturus Therapeutics Holdings' past trends and performance with our Past report.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Bel Fuse Inc. is a company that designs, manufactures, markets, and sells products for powering, protecting, and connecting electronic circuits with a market capitalization of $889.44 million.
Operations: Bel Fuse Inc. generates revenue primarily through its three segments: Power Solutions and Protection ($245.55 million), Connectivity Solutions ($220.37 million), and Magnetic Solutions ($68.87 million).
Bel Fuse, amid a challenging landscape with a 44.5% dip in earnings last year, still shows promise with its recent strategic expansions and leadership transitions poised to steer future growth. The company's revenue is expected to grow by 11.9% annually, outpacing the U.S. market average of 8.3%, while forecasted earnings growth stands at an impressive 23.8% per year. Recent pivotal moves include opening a new facility in India to double manufacturing capacity for its Power Solutions and Protection segment and appointing Farouq Tuweiq as the new CEO after Daniel Bernstein's long tenure, signaling a fresh strategic direction that could invigorate Bel's market position further despite current financial pressures marked by significant one-off losses of $17.4M last year.
Learn about Bel Fuse's historical performance.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: DoubleVerify Holdings, Inc. offers media effectiveness platforms globally and has a market capitalization of $2.22 billion.
Operations: DoubleVerify generates revenue primarily from its data processing segment, which amounts to $656.85 million.
DoubleVerify Holdings, navigating a competitive landscape, has demonstrated resilience with an 11.1% annual revenue growth outstripping the U.S. market's 8.3%. In tandem, its earnings are projected to surge by 20.2% annually, reflecting robust financial health despite a recent dip in net income from $71.47 million to $56.23 million in 2024. The firm's strategic buyback of shares worth $150 million underscores confidence in its trajectory while product enhancements like the expansion into SSPs and new content-level controls for Meta platforms indicate a proactive adaptation to evolving digital advertising dynamics, ensuring better media quality and performance across channels.
Evaluate DoubleVerify Holdings' historical performance by accessing our past performance report.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGM:ARCT NasdaqGS:BELF.A and NYSE:DV.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。